吴媛媛,张菁华,柳志宝,秦策,王洋,李永生,高敬华.Ⅲ、Ⅳ期空洞型肺鳞癌临床特点回顾性研究.[J].中南医学科学杂志.,2016,(1):60-63.
Ⅲ、Ⅳ期空洞型肺鳞癌临床特点回顾性研究
Review the Clinical Features of cSLC at Stage Ⅲ and Ⅳ
投稿时间:2015-07-10  修订日期:2015-09-21
DOI:
中文关键词:  空洞型肺鳞癌  非空洞型肺鳞癌  特征
英文关键词:cSLC  ncSLC  features
基金项目:
作者单位
吴媛媛 沧州市中心医院肿瘤内科,河北 沧州 061001 
张菁华 沧州市中心医院肿瘤内科,河北 沧州 061001 
柳志宝 沧州市中心医院肿瘤内科,河北 沧州 061001 
秦策 沧州市中心医院肿瘤内科,河北 沧州 061001 
王洋 沧州市中心医院肿瘤内科,河北 沧州 061001 
李永生 沧州市中心医院肿瘤内科,河北 沧州 061001 
高敬华 沧州市中心医院肿瘤内科,河北 沧州 061001 
摘要点击次数: 586
全文下载次数: 492
中文摘要:
      目的 探讨Ⅲ、Ⅳ期空洞型肺鳞癌(cSLC)与非空洞型肺鳞癌(ncSLC)患者的临床特点。方法临床分别纳入手术切除的Ⅲ、Ⅳ期cSLC患者21例与ncSLC患者68例,分别对两组患者一般临床情况、病理检查、影像学特征以及生存资料等进行比较分析。结果临床确诊cSLC需要的时间明显长于ncSLC(P<0.05);cSLC患者感染及体质量下降等发生率明显高于ncSLC(P<0.05);cSLC组织细胞的分化程度较ncSLC低,cSLC患者肿瘤体积较大同时伴原发肿瘤范围较广,阻塞性肺炎的临床发生率较高(P<0.05);两组患者年龄、性别、吸烟史、肿瘤家族史、个人结核史、肺内分布、临床病理分期(pTNM)、淋巴结侵犯程度(N)以及远处转移(M)等方面差异均无显著性(P>0.05);cSLC患者中位生存期为29个月,1年、3年生存率分别为85.71%、42.86%%;ncSLC患者中位生存期为35个月,1年、3年生存率分别为91.18%、47.06%(32/68);两者在生存时间上均没有显著差异(P>0.05)。结论与ncSL比较,CcSLC原发肿瘤体积较大、分化程度更低、原发肿瘤的范围更广且容易发生阻塞性肺炎。另外,cSLC还可能因此造成确诊时间延长以及体质量降低等。但是,两者在年龄、性别、吸烟史、肿瘤家族史、个人结核史、肺内分布、pTNM、淋巴结侵犯程度(N)以及远处转移(M)等方面无显著的差异,因此目前尚无足够的证据表明cSLC属于特殊类型的鳞癌。
英文摘要:
      Objective To study the clinical features of cSLC and ncSLC at Stage Ⅲ and Ⅳ.Methods21 cases of ncSLC and 68 cases with cSLC were included in the clinical operation.The general clinical condition,pathological examination,imaging features and survival data of two groups were compared.ResultsThe clinical diagnosis time of cSLC was longer than that of ncSLC; the incidence rate of infection and reduction of body mass for cSLC patients was significantly higher than that of ncSLC patients; the cellular differentiation of cSLC tissue was lower than that of ncSLC; cSLC patients had larger gross tumor volume,larger range of primary tumor and higher incidence rate of obstructive pneumonia.The age,gender,smoking history,family history of tumor,history of tuberculosis,pulmonary distribution,pTNM,N and M of two groups was not significantly different (P>0.05); the median survival time for cSLC patients was 29 months while the survival rate within 1y and 3y was 85.71% and 42.86%; the median survival time for ncSLC patients was 35 months while the survival rate within 1y and 3y was 91.18% and 47.06%(32/68); the survival time of two groups was not significantly different (P>0.05).ConclusionsCompared with ncSLC patients,cSLC patients have larger gross tumor volume,lower cellular differentiation,larger range of primary tumor and higher incidence rate of obstructive pneumonia as well as longer diagnosis time and reduction of body mass.Two groups have no significant differences in terms of age,gender,smoking history,family history of tumor,history of tuberculosis,pulmonary distribution,pTNM,N and M.Therefore,there is no enough evidence to show that cSLC is a special type of squamous cell lung carcinoma.
查看全文  查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=CB8AB70EB9F5E3598A4820C10287C16A01DECDB9863DA0F0836BEF00090A219D3677EF0B9474617FF9225FEE79C95C65A2A7025B27FCA1B829AA3E3B583C7D29&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=BB33F1C95224820A&jid=6A20DF2A798996E24F064D5ECF83A153&yid=9F915C6F01DE79C5&aid=4D3855325A1F235CBD461FAA651CD6E7&vid=&iid=CA4FD0336C81A37A&sid=BFE7933E5EEA150D&eid=E84BBBDDD74F497C&fileno=20160116&flag=1&is_more=0">